Close
FINDING CURES TOGETHER<sup>SM</sup>

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival

Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
The AACR has designated this live activity for a maximum of 24.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Monday, November 2, 2015. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Statement of Educational Need, Target Audience, and Learning Objectives
According to American Cancer Society, in 2015, there will be an estimated 1,658,370 new cancer cases and 585,430 cancer deaths in the US. New strategies and therapeutic options are needed to improve patient survival and quality of life.  Immunotherapy is a promising area that takes advantage of the body's natural defenses to fight cancer.  Scientists are discovering novel therapeutic strategies to harness the power of the immune system to specifically target tumor cells by inducing tumor-specific immune memory for improved regression and complete remission for cancer patients.

New technologies have greatly enhanced our understanding of  immune surveillance and contributed to the development of novel immunotherapies; to further improve the prognosis and outcome of subsequent therapies, it will be important to understand the interaction of tumor cells with the microenvironment.  Adoptive cell therapy (ACT) continues to gain traction and chimeric antigen receptor (CAR)-modified T cells have shown clinical successes in hematopoietic malignancies.  Checkpoint blockade is a promising and active area of research; anti-CTLA-4 antibody is now being used as a first-line treatment for patients with metastatic melanoma. 

To develop more effective therapies for a broader range of cancer types, it is essential to provide a venue for researchers, physician scientists, and all stakeholders, to meet, share novel findings, and have an active exchange of ideas.  This conference, which is the only international event of its kind in the immunotherapy space, will focus on recent advances in cancer immunology and immunotherapy, which includes areas such as:  immune regulation of T cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T cell therapies, checkpoint blockade, adaptive immunity, adoptive T-cell therapies, biomarkers, imaging, combination therapies, viral infections and vaccination, and the microbiome. The potential of immune-based therapeutics will be fully explored and successes in clinical trials and clinical trial design will be discussed. 

After participating in this CME activity, physicians should be able to:

  1. Assess the contribution of tumor microenvironment and microbiome in tumor progression and growth.
  2. Evaluate genomic methods for identifying tumor antigens.

  3. Identify mechanisms involved in the biology of vaccination.

  4. Articulate how checkpoint blockade is being used in a therapeutic setting.

  5. Articulate how recent advances are contributing to personalized cancer immunotherapy.

  6. Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs. 

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgement of Financial or Other Support
This activity is supported by grants which will be disclosed at the activity.

Questions About CME?
Please contact the Office of CME at 215-440-9300 or cme@aacr.org.